Corporate Profile - ds-pharma.com · Corporate Philosophy Corporate Profile Aiming Future Focus Research Areas We formulated our new vision, “For Longer and Healthier Lives: We

Corporate Profile　

Innovation today, healthier tomorrowsThe global slogan with our full commitmentThe global slogan reflects our full commitment to deliver to society revolutionary pharmaceuticals, acquired through groundbreaking ideas and high-standard research and development by each individual employee’ s challenge for innovation, so as to help enable the patients and their families lead healthier and fulfilling lives.

A Message from the President Corporate Philosophy Corporate Profile Corporate History Business Units Aiming Future

My name is Hiroshi Nomura, and I have the honor of serving as Representative Director, President and CEO of Sumitomo Dainippon Pharma Co., Ltd.

The single most important responsibility that I have been given is to ensure the sustainable growth of our company into the future. As such, I will make the most efficient use of all resources available to us, unite our individual strengths, and leverage our wealth of experience so that we can successfully take on this challenge. At the same time, I hope to meet the expectations of all stakeholders in our endeavors to attain this overriding goal.

Sumitomo Dainippon Pharma Co., Ltd., operates every day to achieve its corporate mission “to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide.” By pouring all our efforts into the research and development of new drugs, we aim to provide innovative and valuable pharmaceutical solutions to people not only in Japan but also around the world in order to realize our corporate mission.

We will remain committed to research and development by taking every available opportunity to assimilate cutting-edge technologies through combinations of a wide variety of avenues, including in-house research, technology in-licensing, and joint research with academia and biotech companies, with the aim of continually discovering excellent pharmaceutical products in our focus research areas of Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy. Furthermore, we will explore new businesses in the healthcare sector and offer solutions other than treatment by pharmaceutical products in order to gain opportunities to contribute to the well-being of people through the use of digital technologies and other methods.

Through these undertakings, we will aim to become a “global specialized player” whose presence is felt throughout the world in specific therapeutic areas.

To fulfill our social responsibilities as a corporation, we not only strengthen our corporate governance system and thoroughly ensure compliance but also take wide-ranging initiatives that include social contribution activities in and outside Japan, promotion of diversity and inclusion, and active communication with diverse stakeholders.

Always aware of our responsibility to all of our stakeholders, including patients, their families, medical caregivers, our shareholders, employees, and the communities in which we work, we promise to give our most dedicated efforts to earn and maintain your trust in us.

On behalf of all of us at Sumitomo Dainippon Pharma, I would like to sincerely thank you for your continued support and encouragement.

Hiroshi NomuraRepresentative Director, President and CEOSumitomo Dainippon Pharma Co., Ltd.

A Message from the President

A Message from the President Corporate Philosophy Corporate Profile Corporate History Business Units Aiming Future

To broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide

●To contribute to healthcare and people’ s well-being based upon the principles of patient-oriented management and innovative research

● To continuously strive to maximize corporate value through constant business development and to fulfill shareholder expectations

●To create an environment in which employees can fulfill their potential and increase their creativity●To maintain the trust of society and to contribute to the realization of a better global environment

At Sumitomo Dainippon Pharma, directors and employees alike are determined not only to comply with all laws and regulations, but also to ensure that all corporate activities are carried out in accordance with this Declaration of Conduct. The pledges below express our commitment to earning greater trust from society and becoming a truly innovative company.

1. Follow through the global slogan “Innovation today, healthier tomorrows.”

2. Pursue trustworthy corporate activities.

3. Positively disclose information and properly manage information.

4. Help employees reach their full potential.

5. Respect human rights.

6. Positively address global environmental issues.

7. Build harmonious relationships with society.

Corporate Mission

Management Mission

Declaration ofConduct

ManagementMission

Declaration ofConduct

A Message from the President Corporate Philosophy Corporate Profile

Corporate Philosophy

CorporateMission

Corporate History Business Units Aiming Future

Name Sumitomo Dainippon Pharma Co., Ltd.

Establishment May 14, 1897 Date of merger October 1, 2005 Capitalization 22.4 billion yen Employees 3,067（6,140 : consolidated）（as of March 31, 2019）

Key Facilities 〈Head Offices〉 Osaka Head Office, Tokyo Head Office 〈Branches〉 15 Branches 〈Plants〉 Suzuka Plant, Oita Plant 〈Research Laboratories〉 Central Research Laboratories, Osaka Research Center 〈Distribution Center〉 Kobe Distribution Center, Tokyo Distribution Center

Business（consolidated） Manufacturing and sales of pharmaceuticals, food ingredients, food additives, veterinary medicines and others

Osaka Head Office 6-8, Doshomachi 2-chome, Chuo-ku, Osaka, 541-0045, Japan Tokyo Head Office 13-1, Kyobashi 1-chome, Chuo-ku, Tokyo, 104-8356, Japan

Business Results（Year ended March 31, 2019） Revenue（459.3 billion yen） Core operating profit（77.3 billion yen） R&D expenses（82.9 billion yen）

Segment Revenue

North America　55.0 ％Japan

28.2 ％

Other Business8.3 ％｜

Other Regions3.1 ％

｜

China 5.4 ％


Corporate Profile



Corporate History

Sumitomo Dainippon Pharma created on October 1, 2005.2009 ● Acquired Sepracor Inc., a U.S. company （current Sunovion Pharmaceuticals Inc.）.

2012 ●●

Acquired Boston Biomedical, Inc., a U.S. company.Sunovion Pharmaceuticals Inc. acquired Elevation Pharmaceuticals, Inc., a U.S. company （current Sunovion Respiratory Development Inc.）

2013 ●●

A subsidiary （Sunovion Pharmaceuticals Asia Pacific Pte. Ltd.） established in Singapore.An anti-cancer drugs sales subsidiary company （Boston Biomedical Pharma, Inc） established in the U.S.

2014 ● Joint venture company （Sighregen Co., Ltd.） established.

2016 ● Sunovion Pharmaceuticals Inc. acquired Cynapsus Therapeutics Inc., a Canadian company （current Sunovion CNS Development Canada ULC）.

2017 ● Acquired Tolero Pharmaceuticals, Inc., a U.S. company.

2018 ● Manufacturing Plant for Regenerative Medicine & Cell Therapy （SMaRT） completed.

2019 ●●

Consolidation of production sites. （Reorganized four plants to two plants）With the signing of a strategic alliance agreement with Roivant Sciences, a U.S. subsidiary Sumitovant Biopharma was established to hold shares of Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences.

Dainippon Pharmaceutical

1897● Dainippon Pharmaceutical Co., Ltd., established on May 14.

Twenty-one prominent leaders in the pharmaceutical industry in Doshomachi, Osaka, founded Osaka Pharmaceuticals Co., Ltd.

1898

● Pharmaceutical Plant （former Osaka Plant and former Osaka Center） established in Ebie, Osaka. The company acquired the semi-governmental Dainippon Pharmaceutical Company in Tokyo and changed the name of the company to Dainippon Pharmaceutical Co., Ltd.

Sumitomo Pharmaceuticals

1984

● Sumitomo Pharmaceuticals Co., Ltd., established on February 6, 1984, from the Research, Development, and Manufacturing divisions of Sumitomo Chemical Co., Ltd.’ s pharmaceuticals business, as well as the Pharmaceuticals Sales division of Inabata & Co., Ltd., the sole distributor of Sumitomo Chemical Company’ s pharmaceuticals. The new company opened for business on October 1.



Business Units

In addition to the Psychiatry & Neurology area, we are focusing on Diabetes and Specialty areas （an area with high unmet medical needs in which intensive specialization is required）.

Number of employeesSumitomo Dainippon Pharma: 3,067 （As of March 31, 2019）

Main ProductsTRERIEF®Revenue 15.7 billion yen （FY2018）Launch March 2009

Indications Parkinson’ s disease, Parkinsonism in dementia with Lewy bodies

Features Parkinson’ s disease drug with levodopa-enhancing effect

Trulicity®Revenue 23.1 billion yen （FY2018）Launch September 2015Indications Type 2 diabetes

FeaturesOnce-weekly GLP-1 receptor agonist Provided with a disposable, pen-type auto-injector called Ateos®

Subsidiaries

DSP Gokyo Food & Chemical Co., Ltd. Manufacturing and sales of food ingredients, food additives, chemical product materials, etc.

DS Pharma Animal Health Co., Ltd. Manufacturing, and sales of veterinary medicines, etc.DS Pharma Promo Co., Ltd. Manufacturing and sales of pharmaceuticals, etc.

Regional Strategy in the Mid-term Business Plan 2022 （Japan）Build foundation to achieve 200 billion yen annual revenue target during the next Mid-term Business Plan period

Japan Business

We have a strong platform with head office, sales, and developing functions in Japan, North America, and China.



Business Units

Under the umbrella of Sumitomo Dainippon Pharma America, Inc., a wholly owned holding company, Sunovion Pharmaceuticals Inc. is engaged in manufacturing and sales of pharmaceuticals; Boston Biomedical, Inc. in R&D activities and related marketing preparations in the oncology area; and Tolero Pharmaceuticals, Inc. in R&D activities in the areas of oncology and hematologic malignancy.Under Sumitovant Biopharma, a holding company established in December 2019, Myovant Sciences, Urovant Sciences, Enzyvant Therapeutics, Altavant Sciences, and Spirovant Sciences, all consolidated subsidiaries of Sumitomo Dainippon Pharma, are engaging in pharmaceutical R&D.As for sales, we are focusing on the Respiratory area in addition to the Psychiatry & Neurology area.

Number of employeesSunovion Pharmaceuticals Inc.: 1,683 （As of March 31, 2019）

Main ProductsLATUDA® Revenue 184.5 billion yen （1,663 million dollar）（FY2018）Launch February 2011Indications Schizophrenia, Bipolar I depression

FeaturesAn affinity for dopamine D2, serotonin 5-HT2A and serotonin 5-HT7 receptors where it has antagonist effects

BROVANA® Revenue 33.7 billion yen （304 million dollar）（FY2018）Launch April 2007Indications Chronic Obstructive Pulmonary Disease （COPD）

Features An inhalation solution bronchodilator indicated for the maintenance treatment of COPD

SubsidiariesSunovion Pharmaceuticals Inc. Manufacturing and sales of pharmaceuticals

Sumitovant Biopharma, Inc.

Implement oversight of Sumitovant group companies, formulation of potential business and sales strategies for consideration of its group companies, and promotion of utilization of healthcare technology platforms, etc.

Myovant Sciences Ltd. R&D in the women’ s health, prostate cancer areaUrovant Sciences Ltd. R&D in the urology areaEnzyvant Therapeutics Ltd. R&D in the pediatric rare diseases areaAltavant Sciences Ltd. R&D in the respiratory rare diseases areaSpirovant Sciences Ltd. R&D in the cystic fibrosis gene therapy areaBoston Biomedical, Inc. R&D in the oncology areaTolero Pharmaceuticals, Inc. R&D in the oncology area

Regional Strategy in the Mid-term Business Plan 2022 （North America）Establish post-LATUDA® growth trajectory

North America Business



Business Units

Sumitomo Pharmaceuticals （Suzhou） Co., Ltd. is engaged in manufacturing （subdivided packaging） and sales of pharmaceuticals.

In addition to the Psychiatry & Neurology area, we operate our business with a therapeutic agent for bacterial infections as our main product.

Number of employeesSumitomo Pharmaceuticals （Suzhou） Co., Ltd.: 700 （As of March 31, 2019）

Main productsMEROPEN®（brand name in China: MEPEM®）Revenue 21.2 billion yen （FY2018）Indications General infections, febrile neutropenia

Features Standard therapy for severe infections, used in many countries

SubsidiarySumitomo Pharmaceuticals （Suzhou） Co., Ltd. Manufacturing and sales of pharmaceuticals

Regional Strategy in the Mid-term Business Plan 2022 （China and Asia）Expand presence in growing markets

AsiaReinforce business functions in Singapore subsidiary and established Thailand subsidiary

EuropeExpand business through our commercial footprint plus partnerships

Central and South America, OceaniaCollaborate with partners

China Business

Other Regional Strategies



Aiming Future

Focus Research Areas

We formulated our new vision, “For Longer and Healthier Lives: We unlock the future with cutting-edge tech-

nology and ideas,” to become a company with ability to meet increasingly diversified needs for healthcare.

We aim to become a “global specialized player” whose presence is felt throughout the world in specific thera-

peutic areas.

VisionFor Longer and Healthier Lives

We unlock the future with cutting-edge technology and idea

Position we aspire to establish in 2033Global Specialized Player

Pharmaceuticals + Solutions Global leader in 3 areas

Medicine/Cell Therapy ＋

Healthcare Solution

（Frontier business）

Psychiatry & Neurology Oncology

Regenerative Medicine/Cell

Therapy

Best in class focused on

value＊

＊Best in class: There are existing drugs, but new drugs that have a clear advantage over the existing drugs. We also expect best in class products acquired through a strategic alliance with Roivant Sciences as a growth engine

VisionPosition we aspire to establish in 2033

Focus areas and strengths

Provide new solutions to solve issues in healthcare fields other than pharmaceuticals

Through joint research with academic institutions, conducting drug discovery research to treatment antimicrobial resistance, malaria vaccine and universal influenza vaccine

Frontier business

Infectious DiseasesContribute to global health

＊Unmet medical needs: Medical needs that have not been met yet, that is, medical needs for diseases for which there is still no effective treatments.＊Allogeneic cells: Cells collected from healthy donors other than patients

Mid-term Business Plan 2022 Basic Strategies: Rebuild Business FoundationWe reshape business foundation through the “establishment of growth engine” and the “building of flexible and efficient organization,” preparing for the “Time for Change” and post-LATUDA® revenue replacement.

Psychiatry & Neurology✓ Having our track record of con-

tinually creating products and unique research and develop-ment expertise acquired

✓ Having strengths in drug dis-covery platform that utilize cutting-edge technology

Oncology✓ Working on R&D focusing on

proprietary technologies✓ Having strong collaborative

networks within the Group and with academia and biotech companies

Regenerative Medicine/Cell Therapy✓ Front runner aiming for the com-

mercialization of iPS cell-derived cell therapy products

✓ Created the world’ s first facility dedicated to the commercial manufacture of regenerative med-icine and cell therapy products derived from allogeneic iPS cells


Focus on research areas with high unmet medical needs and focus on creating innovative new drugs.

Documents

Corporate Profile - ds-pharma.com · Corporate Philosophy Corporate Profile Aiming Future Focus Research Areas We formulated our new vision, “For Longer and Healthier Lives: We